Biotech
Biotechnology companies are at the epicenter of innovative drug development, with discoveries spanning from genomic medicines to first-in-class immunotherapies. Typically focused on a small portfolio of compounds, or just a single compound, in a particular therapeutic indication, many biotechs lack the full spectrum of resources or infrastructure required to bring these novel therapies to market.
Helping biotech meet critical milestone
Proven Expertise
-
Biotechnology companies are at the epicenter of innovative drug development, with discoveries spanning from genomic medicines to first-in-class immunotherapies. Typically focused on a small portfolio of compounds, or just a single compound, in a particular therapeutic indication, many biotechs lack the full spectrum of resources or infrastructure required to bring these novel therapies to market.
-
BioFicher helps biotechs to meet their critical milestones and deliver data and evidence-based results to investors, large pharma partners, regulatory authorities, and other stakeholders with responsiveness, accessibility, and true collaboration.
Helping biotech meet critical milestones.
Biotechnology companies are at the epicenter of innovative drug development, with discoveries spanning from genomic medicines to first-in-class immunotherapies. Typically focused on a small portfolio of compounds, or just a single compound, in a particular therapeutic indication, many biotechs lack the full spectrum of resources or infrastructure required to bring these novel therapies to market.
1
Bioficher has the world's largest dedicated biotech division
2,000+
staff dedicated exclusively to biotech customers
500+
Bioficher supports over 500 biotech sponsors annually
Our empowered structure enables flexibility and quick decision-making within the global reach one of the world’s biggest and most innovative CROs. Our biotech division of 2,000+ people operates with a mindset aligned to small and mid-sized biopharma. Our tailored teams and management understand the different pressures that are faced by biotechs and will engage, collaborate and share ownership in the delivery of your clinical trials.
Tailored clinical development
-
Over 100 employees dedicated for biotech clients
-
Highly experience team and program leadership
-
Faster execution through streamlines S.O.P.s.
-
single point of contact and accountability
-
Senior manager tactical involvement.
-
certainty of cost
Consulting & Advisory Services
-
Regulatory and quality assurance strategies submissions manage and ongoing global compliances.
-
Asset development & funding consulting
-
Digital and data analytics capabilities
-
Integrated commercial position to demonstrate the value of your product
Therapeutics Expertise
-
Expert team that proven early-stage and preclinical services to prove assets viability.
-
proven experience across an extensive ranges of therapies, such as cell and gene therapies.
Flexible partnership model for biotech, providing end-to-end integrated services
Our empowered structure enables flexibility and quick decision-making within the global reach one of the world’s biggest and most innovative CROs. Our biotech division of 2,000+ people operates with a mindset aligned to small and mid-sized biopharma. Our tailored teams and management understand the different pressures that are faced by biotechs and will engage, collaborate and share ownership in the delivery of your clinical trials.
2023 biotech sector survey Navigating biotech's challenges and embracing a promising tomorrow
-
Using exclusive data from ICON’s 2023 survey with Citeline, this report presents valuable insights from 133 influential decision-makers within biotech and venture capital organisations from across North America, Europe, and Asia Pacific.
Early engagement and regulatory considerations for biotech
Gain insight into the common questions small and emerging biotech companies face, and the importance of early engagement and regulatory affairs when developing an asset and considering a drug development partner.
Reflections on BioEquity Europe 2023
Gain insight into the common questions small and emerging biotech companies Discover BioFicher’s valuable insights from the 23rd annual Bio€quity Europe conference. As a Regional Host Committee member BioFicher was uniquely placed to evaluate the key trends set to dominate the biotech funding environment's face, and the importance of early engagement and regulatory affairs when developing an asset and considering a drug development partner.
Exploring partnership culture and its impact on outsourcing and operational strategy
Gain insight into the common questions small and emerging biotech companies face, and the importance of early engagement and regulatory affairs when developing an asset and considering a drug development partner.
Procedural and regulatory know-how for China biotechs in the EU
Learn how to navigate the European Medicines Agency registration and regulation procedures and gain access to a potential patient pool of 500 million people.
